PT11.01: Association Between Growth and Differentiation Factor (GDF)-15 Serum Levels, Anorexia and Sarcopenia in Gastrointestinal and Lung Cancer Patients

2019 ◽  
Vol 38 ◽  
pp. S56
Author(s):  
A. Molfino ◽  
M.I. Amabile ◽  
C. Ramaccini ◽  
R. Belli ◽  
A. Di Renzo ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Serum Levels ◽  
Lung Cancer Patients ◽  
Differentiation Factor

scholarly journals Association between Growth Differentiation Factor-15 (GDF-15) Serum Levels, Anorexia and Low Muscle Mass among Cancer Patients

Cancers ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 99
Author(s):  
Alessio Molfino ◽  
Maria Ida Amabile ◽  
Giovanni Imbimbo ◽  
Veronica Rizzo ◽  
Federica Pediconi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Weight Loss ◽  
Body Weight ◽  
Cancer Patients ◽  
Muscle Mass ◽  
Body Weight Loss ◽  
Serum Levels ◽  
Lung Cancer Patients ◽  
Differentiation Factor ◽  
Cancer Anorexia

The pathophysiology of cancer anorexia is complex and serum biomarkers, including growth and differentiation factor(s) (GDF), may be modulated. We explored the association(s) between GDF-15 serum levels and anorexia and, secondarily, with low muscle mass and body weight loss in cancer patients. We considered gastrointestinal and lung cancer patients (CP) and healthy BMI-matched controls. The FAACT-questionnaire was administered to diagnose anorexia and we calculated the L3-SMI by CT scan to assess low muscularity, setting their cutoff values at the lowest tertile. GDF-15 serum levels were assessed by ELISA. We enrolled 59 CP and 30 controls; among CP, 25 were affected by gastrointestinal and 34 by lung cancer. Anorexia was present in 36% of CP. Gastrointestinal CP resulted more anorexic compared to lung CP (p = 0.0067). Low muscle mass was present in 33.9% of CP and L3-SMI was lower in gastrointestinal compared to lung CP (p = 0.049). The GDF-15 levels were higher in CP vs. controls (p = 0.00016), as well as in anorexic vs. non-anorexic CP (p = 0.005) and vs. controls (p < 0.0001). Gastrointestinal CP showed higher GDF-15 levels vs. lung CP (p = 0.0004). No difference was found in GDF-15 between CP with low muscle mass and those with moderate/high muscularity and between patients with body weight loss and those with stable weight. Our data support the involvement of GDF-15 in the pathogenesis of cancer anorexia. The mechanisms of action of GDF-15 in cancer should be further clarified also regarding the changes in muscularity.

Clinical significance of cytokines levels in exhaled breath condensate (EBC) and serum of lung cancer patients.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e22202-e22202
Author(s):  
Georgia Lamprodimou ◽  
Athanasios Athanasiadis ◽  
Theodora Kerenidi ◽  
Dimitrios Doufexis ◽  
Martha Lada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Smoking Status ◽  
Prognostic Significance ◽  
Stage Iv ◽  
Serum Levels ◽  
Rank Test ◽  
Exhaled Breath ◽  
Lower Serum ◽  
Lung Cancer Patients

e22202 Background: Cytokines are known to play an important role in carcinogenesis.The aim of this study is to measure pre-treatment concentrations of cytokines IL6, IL10, IL1β and IL8, in EBC and serum of lung cancer patients and to assess any possible association with clinicopathological variables and survival. Methods: From February 2010 to May 2011 we enrolled 73 patients with previously untreated lung cancer, 67 males and 6 females, age 67.7±9.5 years, 46 smokers and 27 ex-smokers, and 30 healthy individuals as controls. Sixty-one patients had NSCLC and 12 SCLC (5 stage I, 3 stage II, 19 stage III and 46 stage IV). EBC was collected using the Ecoscreen device (Viasys, Germany). Serum and EBC levels of cytokines were analyzed by commercially available enzyme-immunosorbent assay kits (ELISA). Results: All cytokines but IL8 were detectable in both materials. IL8 was not detected in EBC. All cytokines were significantly increased in patients with lung cancer in comparison to controls (IL6: serum P<0.0001, EBC P=0.001; IL10: serum P= 0.006, EBC P=0.037; IL1β: serum P= 0.032, EBC P=0.005; IL8 serum P=0.001). Moreover, a statistically significant correlation was found between IL10 levels in EBC and serum (P=0.001, Rho=0.334). In EBC, higher levels of IL6 were found in patients with T3-T4 disease than in those with T1-T2 [4.27 pg/ml (2.46-5.99) vs 3.12 pg/ml (1.35-5.03), P=0.036]. Furthermore, smokers had higher serum levels of IL6 compared to ex-smokers [10.19 pg/ml (4.92-17.38) vs 4.46 pg/ml (1.88-11.53), P=0.009]. Finally, lower serum levels of IL6 < median value (9.55pg/ml) were associated with improved survival (median overall survival 338 days vs 237 days Log Rank test, P= 0.046). Conclusions: Elevated levels of measured cytokines were found in both EBC and serum of lung cancer patients. Particularly, IL6 levels were related to T-stage and smoking status, while lower serum levels of IL6 with survival. These findings suggest that cytokines should be further studied in order to evaluate their diagnostic and prognostic significance. EBC could provide a simple, noninvasive and economic method for the monitoring of biomarkers in patients with lung cancer.

Elevated Serum Levels of Interleukin-8 in Advanced Non-Small Cell Lung Cancer Patients: Relationship with Prognosis

2002 ◽  
Vol 22 (11) ◽  
pp. 1129-1135 ◽  
Author(s):  
Michele Orditura ◽  
Ferdinando De Vita ◽  
Giuseppe Catalano ◽  
Stefania Infusino ◽  
Eva Lieto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Elevated Serum ◽  
Serum Levels ◽  
Small Cell ◽  
Interleukin 8 ◽  
Small Cell Lung ◽  
Lung Cancer Patients

Vascular Endothelial Growth Factor (VEGF) Serum Levels Are Associated With Survival in Early Stages of Lung Cancer Patients

2010 ◽  
Vol 28 (4) ◽  
pp. 393-398 ◽  
Author(s):  
Enrique Carrillo-de Santa Pau ◽  
Fernando Carrillo Arias ◽  
Enrique Caso Pelaez ◽  
Ignacio Muguruza Trueba ◽  
Ignacio Sánchez Hernández ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Lung Cancer Patients ◽  
Early Stages ◽  
Endothelial Growth Factor

scholarly journals Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients

2002 ◽  
Vol 86 (6) ◽  
pp. 858-863 ◽  
Author(s):  
R Jäger ◽  
B List ◽  
C Knabbe ◽  
B Souttou ◽  
D Raulais ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Serum Levels ◽  
Angiogenic Factor ◽  
Disease Stage ◽  
Lung Cancer Patients

scholarly journals Serum levels of cystatin C in elderly lung cancer patients

2011 ◽  
Vol 3 (2) ◽  
pp. 303-306 ◽  
Author(s):  
GEN OHARA ◽  
KUNIHIKO MIYAZAKI ◽  
KOICHI KURISHIMA ◽  
KATSUNORI KAGOHASHI ◽  
HIROICHI ISHIKAWA ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cystatin C ◽  
Serum Levels ◽  
Lung Cancer Patients

scholarly journals Decreased Thrombospondin-1 and Bone Morphogenetic Protein-4 Serum Levels as Potential Indices of Advanced Stage Lung Cancer

2021 ◽  
Vol 10 (17) ◽  
pp. 3859
Author(s):  
Monika Kosacka ◽  
Tomasz Dyła ◽  
Monika Chaszczewska-Markowska ◽  
Katarzyna Bogunia-Kubik ◽  
Anna Brzecka
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Serum Levels ◽  
Small Cell ◽  
Bone Morphogenetic Protein 4 ◽  
Advanced Stage ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Morphogenetic Protein

Introduction: Lung cancer belongs to the most common carcinoma worldwide and is the leading cause of cancer-related death. Bone morphogenetic protein-4 (BMP-4) is extracellular signaling molecule involved in many important processes, including cell proliferation and mobility, apoptosis and angiogenesis. Thrombospondin-1 (TSP-1) belongs to the extracellular matrix proteins. It participates in the cell-to-cell and cell-to-matrix interactions and thus plays important role in tumor microenvironment for cancer development and metastasis formation. Aim: To investigate serum levels of TSP-1 and BMP-4 together with BMP-4 polymorphism in lung cancer patients. Material and Methods: A total of 111 patients (76 men) with newly diagnosed lung cancer, including 102 patients with non-small cell lung cancer and 9 patients with small-cell lung cancer. Advanced stage of lung cancer was diagnosed in 99 (89%) of patients: stage IV—in 48, stage IIIB—in 33, stage IIIA—in 18 patients; there were six patients with stage II and six patients with stage I. The control group consisted of 61 healthy persons. In all the subjects, serum levels of BMP-4 and TSP-1 were measured by ELISA. With a Real-Time PCR system genotyping of BMP-4 was performed. Results: BMP-4 and TSP-1 serum levels were significantly lower in the patients with lung cancer than in the controls (TSP-1:10,109.2 ± 9581 ng/mL vs. 11,415.09 ± 9781 ng/mL, p < 0.05; BMP-4: 138.35 ± 62.59 pg/mL vs. 226.68 ± 135.86 pg/mL p < 0.001). In lung cancer patients TSP-1 levels were lower in advanced stages (9282.07 ± 4900.78 ng/mL in the stages III-IV vs. 16,933.60 ± 6299.02 ng/mL in the stages I-II, p < 0.05) and in the patients with than without lymph nodes involvement (10,000.13 ± 9021.41 ng/mL vs. 18,497.75 ± 12,548.25 ng/mL, p = 0.01). There was no correlation between TSP-1 and BMP-4 serum levels. BMP-4 gene polymorphism did not influence the results of the study. Conclusion: Decreased levels of TSP-1 and BMP-4 may serve as potential indices of lung cancer, with additional importance of low TSP-1 level as a marker of advanced stage of the disease.

The Effects of Serum hs-CRP on the Incidence of Lung Cancer in Male Patients with Pulmonary Tuberculosis

2020 ◽  
Author(s):  
Youhua JIANG ◽  
Kewei NI ◽  
Meiyu FANG ◽  
Junling LIU
Keyword(s):  
Lung Cancer ◽  
Pulmonary Tuberculosis ◽  
Cancer Patients ◽  
Serum Levels ◽  
Incidence Rates ◽  
Lung Cancer Patients ◽  
Group A ◽  
Male Patients ◽  
Hs Crp ◽  
Group B

Background: This study intended to investigate the effects of serum high-sensitivity C-reactive protein (hs-CRP) on the incidence of lung cancer in male patients with pulmonary tuberculosis. Methods: A total of 1091 male patients with pulmonary tuberculosis in Zhejiang Cancer Hospital, Hangzhou, China from Jan 2009 to Jan 2012 were selected as the research objects. All patients were followed up from the beginning of hospitalization. According to serum hs-CRP level, patients were divided into two groups: group A (hs-CRP < 1 mg/L) and group B (hs-CRP > 3 mg/L). The relationship between baseline hs-CRP and the risk of lung cancer in patients with pulmonary tuberculosis was analyzed by multivariate Cox proportional risk regression model, and the serum levels of hs-CRP between lung cancer patients in all groups and other non-lung cancer patients were compared. Results: There were differences in age, drinking, smoking, diabetes history, body mass index (BMI), thyroglobulin (TG), history of hypertension and hyperglycemia among the three groups (P=0.036, 0.018, 0.040, 0.029, 0.006, 0.034, 0.020, 0.010). The serum levels of hs-CRP in patients with squamous carcinoma, adenocarcinoma and small cell carcinoma were significantly higher than those in non-lung cancer patients (P=0.022, 0.043, 0.011). The incidence rates of lung cancer in patients in group B and C were 1.37 and 1.69 times higher than that in group A, respectively. Conclusion: The increased serum level of hs-CRP will increase the incidence rate of lung cancer in male patients with pulmonary tuberculosis.

scholarly journals Relationship between depression and blood cytokine levels in lung cancer patients

2018 ◽  
Vol 34 ◽  
pp. 113-115 ◽  
Author(s):  
Wen-Juan Liu ◽  
Xiao-Dan Wang ◽  
Wei Wu ◽  
Xiao Huang
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Rating Scale ◽  
Serum Levels ◽  
Advanced Lung Cancer ◽  
Control Group ◽  
Mild Depression ◽  
Lung Cancer Patients ◽  
Tnf Α ◽  
Cytokine Levels

Objective: To study the correlation between depression and blood cytokine levels in lung cancer patients.Methods: 92 patients with advanced lung cancer were evaluated for depression using the scoring index of depression self-rating scale. Lack of depression (n=24), mild depression (n=45), and moderate depression (n=23) were found in the cohort. Meanwhile, 40 healthy subjects were selected as the control group. The levels of IL-10, IL-6, IL-8, and TNF-α in each group were detected by sandwich enzyme-linked immunosorbent assays, and their correlation with the degree of depression was analyzed.Results: The levels of IL-10, IL-6, IL-8, and TNF-α were all higher than those in the control group (P<0.05). Moreover, the depression statuses of patients with lung cancer were positively correlated with IL-10, IL-6, and TNF-α levels (r = 0.705, 0.301, and 0.446, P<0.01); however, the level of IL-8 was not relevant (r=0.136, p>0.05).Conclusion: Serum levels of IL-10, IL-6, and TNF-α are associated with depression scoring in patients with lung cancer.

Sign in / Sign up

Export Citation Format

Share Document